Kolexia
Defer Gilles Neurologie
Defer Gilles
Neurologie
Hôpital Côte de Nacre
Caen, France
208 Activités
157 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Sclérose en plaques Sclérose Sclérose en plaques récurrente-rémittente Sclérose en plaques chronique progressive Leucoencéphalopathie multifocale progressive Maladie de Parkinson Fatigue Démence Névrite optique

Collaborateurs

Voir plus
De Sèze Jérôme
De Sèze Jérôme
Hôpital Hautepierre, Strasbourg, France
Clavelou Pierre
Clavelou Pierre
Hôpital Gabriel Montpied, Clermont-Ferrand, France
Pelletier Jean
Pelletier Jean
Hôpital La Timone, Marseille, France
Frenay Christine
Frenay Christine
Hôpital Pasteur, Nice, France

Industries

Voir plus
Novartis
28 collaboration(s)
Dernière en 2023
Biogen
17 collaboration(s)
Dernière en 2023
Merck-Serono
15 collaboration(s)
Dernière en 2023
BMS
11 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society.
Multiple sclerosis (Houndmills, Basingstoke, England)   15 février 2024
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.
JAMA neurology   12 février 2024
SEPIA: Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme
Essai Clinique (CHU Caen)   12 février 2024
RESPONSE: French Registry for Monitoring Pregnancies and Children of Women With Multiple Sclerosis Within The Observatoire Français de la Sclérose en Plaque (OFSEP) Cohort
Essai Clinique (Hospices Civils de Lyon)   25 janvier 2024
A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration: A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing (EID) of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment - Followed by an Open-Label Crossover Extension Study Comprising Subcutaneous and Intravenous Natalizumab Administration
Essai Clinique (Biogen)   24 janvier 2024
Neurological disorders related to recreational nitrous oxide abuse: Two sides of the same coin.
Revue neurologique   04 décembre 2023
Correction: Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis.
Neurology and therapy   20 novembre 2023
Comparison of Two Methods for Estimating MS-Related Mortality: The Excess Mortality vs. the Cause-Specific Frameworks.
Neurology   12 octobre 2023
POLAR: Tear Analysis by Isoelectric Focusing in Clinically Isolated Syndrome as Multiple Sclerosis Criterion Among Patients With or Without Lesions at the Magnetic Resonance Imaging (Oligoclonal Profile of Tears)
Essai Clinique (Lille Catholic University)   12 septembre 2023
Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis.
Neurology and therapy   29 juin 2023